6.
Madan S, Mehra M
. Gut dysbiosis and heart failure: navigating the universe within. Eur J Heart Fail. 2020; 22(4):629-637.
DOI: 10.1002/ejhf.1792.
View
7.
Ebner N, Foldes G, Schomburg L, Renko K, Springer J, Jankowska E
. Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure. J Mol Cell Cardiol. 2015; 87:48-53.
DOI: 10.1016/j.yjmcc.2015.07.029.
View
8.
Carpino G, Ben M, Pastori D, Carnevale R, Baratta F, Overi D
. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2019; 72(2):470-485.
DOI: 10.1002/hep.31056.
View
9.
Frantz S, Ertl G, Bauersachs J
. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007; 4(8):444-54.
DOI: 10.1038/ncpcardio0938.
View
10.
El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa G
. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002; 123(5):1607-15.
DOI: 10.1053/gast.2002.36578.
View
11.
Perticone M, Zito R, Miceli S, Pinto A, Suraci E, Greco M
. Immunity, Inflammation and Heart Failure: Their Role on Cardiac Function and Iron Status. Front Immunol. 2019; 10:2315.
PMC: 6779858.
DOI: 10.3389/fimmu.2019.02315.
View
12.
Tang W, Backhed F, Landmesser U, Hazen S
. Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73(16):2089-2105.
PMC: 6518422.
DOI: 10.1016/j.jacc.2019.03.024.
View
13.
Dick S, Epelman S
. Chronic Heart Failure and Inflammation: What Do We Really Know?. Circ Res. 2016; 119(1):159-76.
DOI: 10.1161/CIRCRESAHA.116.308030.
View
14.
Bezhaeva T, Karper J, Quax P, de Vries M
. The Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease. Front Cardiovasc Med. 2022; 9:820962.
PMC: 8884272.
DOI: 10.3389/fcvm.2022.820962.
View
15.
Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F
. Pathogenic Gut Flora in Patients With Chronic Heart Failure. JACC Heart Fail. 2015; 4(3):220-7.
DOI: 10.1016/j.jchf.2015.10.009.
View
16.
Mann D
. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015; 116(7):1254-68.
PMC: 4380242.
DOI: 10.1161/CIRCRESAHA.116.302317.
View
17.
Van Linthout S, Tschope C
. Inflammation - Cause or Consequence of Heart Failure or Both?. Curr Heart Fail Rep. 2017; 14(4):251-265.
PMC: 5527060.
DOI: 10.1007/s11897-017-0337-9.
View
18.
Seferovic P, Ponikowski P, Anker S, Bauersachs J, Chioncel O, Cleland J
. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(10):1169-1186.
DOI: 10.1002/ejhf.1531.
View
19.
Carpes L, Nicoletto B, Canani L, Rheinhemer J, Crispim D, Souza G
. Could serum zonulin be an intestinal permeability marker in diabetes kidney disease?. PLoS One. 2021; 16(6):e0253501.
PMC: 8232531.
DOI: 10.1371/journal.pone.0253501.
View
20.
Jayashree B, Bibin Y, Prabhu D, Shanthirani C, Gokulakrishnan K, Lakshmi B
. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2013; 388(1-2):203-10.
DOI: 10.1007/s11010-013-1911-4.
View